Cargando…
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)
The advancement of new therapies, including targeted therapies and immunotherapies, has improved the survival of non-small-cell lung cancer (NSCLC) patients in the last decade. Some NSCLC patients still do not benefit from therapies or encounter progressive disease during the course of treatment bec...
Autores principales: | Hsu, Ping-Chih, Yang, Cheng-Ta, Jablons, David M., You, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352956/ https://www.ncbi.nlm.nih.gov/pubmed/32466572 http://dx.doi.org/10.3390/cancers12061361 |
Ejemplares similares
-
Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells
por: You, Bin, et al.
Publicado: (2015) -
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
por: Hsu, Ping-Chih, et al.
Publicado: (2019) -
The Crosstalk Between Hippo-YAP Pathway and Innate Immunity
por: Wang, Shuai, et al.
Publicado: (2020) -
The Biology and Therapeutic Potential of the Src-YAP Axis in Non-Small Cell Lung Cancer (NSCLC)
por: Papavassiliou, Kostas A., et al.
Publicado: (2022) -
Role of Hippo-YAP1/TAZ pathway and its crosstalk in cardiac biology
por: Chen, Xiaoqing, et al.
Publicado: (2020)